Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. reported a Form 4 showing a compensation-related stock option grant tied to entities associated with RA Capital. A stock option for 19,475 shares of Common Stock was granted to director Jake Simson at an exercise price of $20.56 per share, expiring on June 9, 2036. The option vests upon the earlier of June 9, 2027 or the next annual stockholders’ meeting, subject to his continued service. Under Dr. Simson’s arrangement, any net cash or stock from exercising the option is turned over to RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP to offset advisory fees. The reporting persons, including RA Capital Management, L.P. and its principals, disclaim beneficial ownership except for any pecuniary interest.
Bicara Therapeutics Inc. director Christopher Bowden reported a new stock option grant. He received options to buy 19,475 shares of common stock at an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest on the earlier of June 9, 2027 or the date of Bicara’s next Annual Meeting of Stockholders, if he continues serving through that date. Following this grant, Bowden holds stock options covering 19,475 shares directly.
Bicara Therapeutics Inc. director Kate Haviland received a stock option grant giving her the right to buy 19,475 shares of common stock at an exercise price of $20.56 per share. These options were granted at no cost and represent a compensation award rather than an open-market purchase.
The 19,475 underlying shares vest on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided she continues serving as a director through that vesting date. Following this grant, her reported option holdings from this award total 19,475 shares.
Bicara Therapeutics Inc. director Kiran Mazumdar-Shaw received a stock option grant covering 19,475 shares of common stock. The option has an exercise price of $20.56 per share and expires on June 9, 2036.
The shares underlying this option vest on the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to her continued service on that vesting date. Following this grant, she holds 19,475 derivative securities directly.
Bicara Therapeutics Inc. director Robertson Scott M. received a grant of stock options on Common Stock. The award covers 19,475 stock options with an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest upon the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. Following this grant, he holds 19,475 stock options directly.
Bicara Therapeutics Inc. director Michael Powell received a grant of stock options as part of his compensation. The award covers 19,475 options to buy common stock at an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest upon the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, conditional on his continued service. After this grant, Powell holds 19,475 derivative securities directly, reflecting a routine equity incentive rather than an open-market purchase or sale.
Bicara Therapeutics Inc. reported that director Jake Simson was granted a stock option for 19,475 shares of common stock at an exercise price of $20.56 per share. The option vests on the earlier of June 9, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.
According to the disclosed arrangement, Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. and must turn over any net cash or stock received upon exercise to RA Capital Management, L.P., and therefore disclaims beneficial ownership of the option and underlying shares.
Bicara Therapeutics Inc. held its 2026 annual meeting of stockholders on June 9, 2026. Of 65,600,370 common shares outstanding as of the record date, 55,924,987 shares, or about 85.25%, were present or represented.
Stockholders elected Christopher Bowden, M.D., and Carolyn Ng, Ph.D., as Class II directors to serve until the 2029 annual meeting, with each receiving substantially more votes for than withheld. Stockholders also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Bicara Therapeutics Inc.’s Chief Financial Officer Hyep Ivan reported a combination of option exercise and share sale. Ivan exercised stock options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold 9,200 shares in an open-market transaction at a weighted average price of $20.4221 per share.
The sale was executed on May 21, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and retains stock options covering 70,584 shares expiring on August 8, 2033, which vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service.